Human T cell leukemia virus type I-induced disease: Pathways to cancer and neurodegeneration

Kate Barmak, Edward Harhaj, Christian Grant, Timothy Alefantis, Brian Wigdahl

Research output: Contribution to journalShort survey

72 Citations (Scopus)

Abstract

Retroviral infection is associated with a number of pathologic abnormalities, including a variety of cancers, immunologic diseases, and neurologic disorders. Shortly after its discovery in 1980, human T cell leukemia virus type I (HTLV-I) was found to be the etiologic agent of both adult T cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a neurologic disease characterized by demyelinating lesions in both the brain and the spinal cord. Approximately 5-10% of HTLV-I-infected individuals develop either ATL or HAM/TSP. Interestingly, the two diseases have vastly different pathologies and have rarely been found to occur within the same individual. While a number of host and viral factors including virus strain, viral load, and HLA haplotype have been hypothesized to influence disease outcome associated with HTLV-I infection, the relative contributions of such factors to disease pathogenesis have not been fully established. Recent research has suggested that the route of primary viral infection may dictate the course of disease pathogenesis associated with HTLV-I infection. Specifically, mucosal exposure to HTLV-I has been associated with cases of ATL, while primary viral infection based in the peripheral blood has been correlated with progression to HAM/TSP. However, the cellular and molecular mechanisms regulating disease progression resulting from primary viral invasion remain to be elucidated. Although a variety of factors likely influence these mechanisms, the differential immune response mounted by the host against the incoming virus initiated in either the peripheral blood or the mucosal compartments likely plays a key role in determining the outcome of HTLV-I infection. It has been proposed that the route of infection and size of the initial viral inoculum allows HTLV-I to infect different target cell populations, in turn influencing the breadth of the immune response mounted against HTLV-I and affecting disease pathogenesis. A model of HTLV-I-induced disease progression is presented, integrating information regarding the role of several host and viral factors in the genesis of both neoplasia and neurologic disease induced following HTLV-I infection, focusing specifically on differential viral invasion into the bone marrow (BM) and the influence of this event on the virus-specific CD8+ cytotoxic T lymphocyte (CTL) response that is initiated following HTLV-I infection.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalVirology
Volume308
Issue number1
DOIs
StatePublished - Mar 30 2003

Fingerprint

Human T-lymphotropic virus 1
Virus Diseases
Neoplasms
Tropical Spastic Paraparesis
Adult T Cell Leukemia Lymphoma
Nervous System Diseases
Viruses
Disease Progression
Spinal Cord Diseases
Health Services Needs and Demand
Immune System Diseases
Cytotoxic T-Lymphocytes
Infection
Viral Load
Haplotypes
Spinal Cord
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Virology

Cite this

Barmak, Kate ; Harhaj, Edward ; Grant, Christian ; Alefantis, Timothy ; Wigdahl, Brian. / Human T cell leukemia virus type I-induced disease : Pathways to cancer and neurodegeneration. In: Virology. 2003 ; Vol. 308, No. 1. pp. 1-12.
@article{ea135dd016c641f6bfa45fe5cccfe178,
title = "Human T cell leukemia virus type I-induced disease: Pathways to cancer and neurodegeneration",
abstract = "Retroviral infection is associated with a number of pathologic abnormalities, including a variety of cancers, immunologic diseases, and neurologic disorders. Shortly after its discovery in 1980, human T cell leukemia virus type I (HTLV-I) was found to be the etiologic agent of both adult T cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a neurologic disease characterized by demyelinating lesions in both the brain and the spinal cord. Approximately 5-10{\%} of HTLV-I-infected individuals develop either ATL or HAM/TSP. Interestingly, the two diseases have vastly different pathologies and have rarely been found to occur within the same individual. While a number of host and viral factors including virus strain, viral load, and HLA haplotype have been hypothesized to influence disease outcome associated with HTLV-I infection, the relative contributions of such factors to disease pathogenesis have not been fully established. Recent research has suggested that the route of primary viral infection may dictate the course of disease pathogenesis associated with HTLV-I infection. Specifically, mucosal exposure to HTLV-I has been associated with cases of ATL, while primary viral infection based in the peripheral blood has been correlated with progression to HAM/TSP. However, the cellular and molecular mechanisms regulating disease progression resulting from primary viral invasion remain to be elucidated. Although a variety of factors likely influence these mechanisms, the differential immune response mounted by the host against the incoming virus initiated in either the peripheral blood or the mucosal compartments likely plays a key role in determining the outcome of HTLV-I infection. It has been proposed that the route of infection and size of the initial viral inoculum allows HTLV-I to infect different target cell populations, in turn influencing the breadth of the immune response mounted against HTLV-I and affecting disease pathogenesis. A model of HTLV-I-induced disease progression is presented, integrating information regarding the role of several host and viral factors in the genesis of both neoplasia and neurologic disease induced following HTLV-I infection, focusing specifically on differential viral invasion into the bone marrow (BM) and the influence of this event on the virus-specific CD8+ cytotoxic T lymphocyte (CTL) response that is initiated following HTLV-I infection.",
author = "Kate Barmak and Edward Harhaj and Christian Grant and Timothy Alefantis and Brian Wigdahl",
year = "2003",
month = "3",
day = "30",
doi = "10.1016/S0042-6822(02)00091-0",
language = "English (US)",
volume = "308",
pages = "1--12",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

Human T cell leukemia virus type I-induced disease : Pathways to cancer and neurodegeneration. / Barmak, Kate; Harhaj, Edward; Grant, Christian; Alefantis, Timothy; Wigdahl, Brian.

In: Virology, Vol. 308, No. 1, 30.03.2003, p. 1-12.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Human T cell leukemia virus type I-induced disease

T2 - Pathways to cancer and neurodegeneration

AU - Barmak, Kate

AU - Harhaj, Edward

AU - Grant, Christian

AU - Alefantis, Timothy

AU - Wigdahl, Brian

PY - 2003/3/30

Y1 - 2003/3/30

N2 - Retroviral infection is associated with a number of pathologic abnormalities, including a variety of cancers, immunologic diseases, and neurologic disorders. Shortly after its discovery in 1980, human T cell leukemia virus type I (HTLV-I) was found to be the etiologic agent of both adult T cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a neurologic disease characterized by demyelinating lesions in both the brain and the spinal cord. Approximately 5-10% of HTLV-I-infected individuals develop either ATL or HAM/TSP. Interestingly, the two diseases have vastly different pathologies and have rarely been found to occur within the same individual. While a number of host and viral factors including virus strain, viral load, and HLA haplotype have been hypothesized to influence disease outcome associated with HTLV-I infection, the relative contributions of such factors to disease pathogenesis have not been fully established. Recent research has suggested that the route of primary viral infection may dictate the course of disease pathogenesis associated with HTLV-I infection. Specifically, mucosal exposure to HTLV-I has been associated with cases of ATL, while primary viral infection based in the peripheral blood has been correlated with progression to HAM/TSP. However, the cellular and molecular mechanisms regulating disease progression resulting from primary viral invasion remain to be elucidated. Although a variety of factors likely influence these mechanisms, the differential immune response mounted by the host against the incoming virus initiated in either the peripheral blood or the mucosal compartments likely plays a key role in determining the outcome of HTLV-I infection. It has been proposed that the route of infection and size of the initial viral inoculum allows HTLV-I to infect different target cell populations, in turn influencing the breadth of the immune response mounted against HTLV-I and affecting disease pathogenesis. A model of HTLV-I-induced disease progression is presented, integrating information regarding the role of several host and viral factors in the genesis of both neoplasia and neurologic disease induced following HTLV-I infection, focusing specifically on differential viral invasion into the bone marrow (BM) and the influence of this event on the virus-specific CD8+ cytotoxic T lymphocyte (CTL) response that is initiated following HTLV-I infection.

AB - Retroviral infection is associated with a number of pathologic abnormalities, including a variety of cancers, immunologic diseases, and neurologic disorders. Shortly after its discovery in 1980, human T cell leukemia virus type I (HTLV-I) was found to be the etiologic agent of both adult T cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a neurologic disease characterized by demyelinating lesions in both the brain and the spinal cord. Approximately 5-10% of HTLV-I-infected individuals develop either ATL or HAM/TSP. Interestingly, the two diseases have vastly different pathologies and have rarely been found to occur within the same individual. While a number of host and viral factors including virus strain, viral load, and HLA haplotype have been hypothesized to influence disease outcome associated with HTLV-I infection, the relative contributions of such factors to disease pathogenesis have not been fully established. Recent research has suggested that the route of primary viral infection may dictate the course of disease pathogenesis associated with HTLV-I infection. Specifically, mucosal exposure to HTLV-I has been associated with cases of ATL, while primary viral infection based in the peripheral blood has been correlated with progression to HAM/TSP. However, the cellular and molecular mechanisms regulating disease progression resulting from primary viral invasion remain to be elucidated. Although a variety of factors likely influence these mechanisms, the differential immune response mounted by the host against the incoming virus initiated in either the peripheral blood or the mucosal compartments likely plays a key role in determining the outcome of HTLV-I infection. It has been proposed that the route of infection and size of the initial viral inoculum allows HTLV-I to infect different target cell populations, in turn influencing the breadth of the immune response mounted against HTLV-I and affecting disease pathogenesis. A model of HTLV-I-induced disease progression is presented, integrating information regarding the role of several host and viral factors in the genesis of both neoplasia and neurologic disease induced following HTLV-I infection, focusing specifically on differential viral invasion into the bone marrow (BM) and the influence of this event on the virus-specific CD8+ cytotoxic T lymphocyte (CTL) response that is initiated following HTLV-I infection.

UR - http://www.scopus.com/inward/record.url?scp=0037473284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037473284&partnerID=8YFLogxK

U2 - 10.1016/S0042-6822(02)00091-0

DO - 10.1016/S0042-6822(02)00091-0

M3 - Short survey

C2 - 12706085

AN - SCOPUS:0037473284

VL - 308

SP - 1

EP - 12

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -